1. The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry
- Author
-
Musters, A. H., Broderick, C., Prieto-Merino, D., Chiricozzi, Andrea, Damiani, G., Peris, Ketty, Dhar, S., De, A., Freeman, E., Arents, B. W. M., Burton, T., Bosma, A. L. -A. L., Chi, C. -C., Fletcher, G., Drucker, A. M., Kabashima, K., de Monchy, E. F., Panda, M., Wall, D. R., Vestergaard, C., Mahe, E., Bonzano, L., Kattach, L., Napolitano, M., Ordonez-Rubiano, M. F., Haufe, E., Patruno, C., Irvine, A. D., Spuls, P. I., Flohr, C., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Musters, A. H., Broderick, C., Prieto-Merino, D., Chiricozzi, Andrea, Damiani, G., Peris, Ketty, Dhar, S., De, A., Freeman, E., Arents, B. W. M., Burton, T., Bosma, A. L. -A. L., Chi, C. -C., Fletcher, G., Drucker, A. M., Kabashima, K., de Monchy, E. F., Panda, M., Wall, D. R., Vestergaard, C., Mahe, E., Bonzano, L., Kattach, L., Napolitano, M., Ordonez-Rubiano, M. F., Haufe, E., Patruno, C., Irvine, A. D., Spuls, P. I., Flohr, C., Chiricozzi A. (ORCID:0000-0002-6739-0387), and Peris K. (ORCID:0000-0002-5237-0463)
- Abstract
Background: Limited data are available on the effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis (AD). Objective: To investigate COVID-19 outcomes in patients with AD treated with or without systemic immunomodulatory treatments, using a global registry platform. Methods: Clinicians were encouraged to report cases of COVID-19 in their patients with AD in the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Atopic Dermatitis (SECURE-AD) registry. Data entered from 1 April 2020 to 31 October 2021 were analysed using multivariable logistic regression. The primary outcome was hospitalization from COVID-19, according to AD treatment groups. Results: 442 AD patients (mean age 35.9 years, 51.8% male) from 27 countries with strongly suspected or confirmed COVID-19 were included in analyses. 428 (96.8%) patients were treated with a single systemic therapy (n = 297 [67.2%]) or topical therapy only (n = 131 [29.6%]). Most patients treated with systemic therapies received dupilumab (n = 216). Fourteen patients (3.2%) received a combination of systemic therapies. Twenty-six patients (5.9%) were hospitalized. No deaths were reported. Patients treated with topical treatments had significantly higher odds of hospitalization, compared with those treated with dupilumab monotherapy (odds ratio (OR) 4.65 [95%CI 1.71–14.78]), including after adjustment for confounding variables (adjusted OR (aOR) 4.99 [95%CI 1.4–20.84]). Combination systemic therapy which did not include systemic corticosteroids was associated with increased odds of hospitalization, compared with single agent non-steroidal immunosuppressive systemic treatment (OR 8.09 [95%CI 0.4–59.96], aOR 37.57 [95%CI 1.05–871.11]). Hospitalization was most likely in patients treated with combination systemic therapy which included systemic corticosteroids (OR 40.43 [95%CI 8.16–207.49], aOR 45.75 [95%CI 4.54–616.22]). Conclusions: Overall, the risk
- Published
- 2023